Company Update | Navigation Sciences Selected for NCI Showcase

Dear Friend of Navigation Sciences,

I hope you had a pleasant summer and are off to a productive start in the final months of the year. Navigation Sciences continues to make steady progress in developing the NaviSci™ System for precision surgical oncology, soft-tissue tumor localization and resection, and advancing our regulatory and commercialization strategy.

Looking ahead, our primary focus is advancing the NaviSci™ System toward FDA clearance while continuing product development and preparing for early commercialization. We are also actively pursuing additional financing and strategic partnerships to support these milestones.

NATIONAL CANCER INSTITUTE
SBIR Development Center

I'm pleased to share that the National Cancer Institute (NCI) recently selected Navigation Sciences as a "Showcase Company." We were one of 30 SBIR/STTR grantee companies selected through a peer-review process involving more than 70 investors and strategic industry participants, based on our readiness to attract additional financing and/or strategic partnerships.

As part of the Showcase program, NCI will support our participation in investor and industry conferences through the summer of 2027. Our first NCI-sponsored presentation will be at MedTech Strategist's Innovation Summit, November 3–5, 2026, in San Diego, with NCI covering our presentation and registration fees.

Our eligibility for the Showcase program was based on the $400,000 Phase I STTR grant Navigation recently received to support development of the NaviSci EndoMarker™. The technology is designed to simplify clinical workflow by enabling placement, via bronchoscopy, of a sensorized marker near a tumor nodule based on diagnostic CT imaging. This is the second $400,000 STTR grant Navigation has received to advance this technology.

We will also participate in The MedTech Conference, hosted by AdvaMed, October 18–21 at the Boston Convention & Exhibition Center. With more than 4,000 medtech leaders and 1,800 companies expected to participate, the conference provides an excellent opportunity to meet with potential strategic partners, investors, and industry leaders.

If you are attending either conference, I would be pleased to meet with you and provide a more detailed update on the company.

Read our updated Executive Summary and our Precision Surgical Oncology White Paper, both also available on our website. These materials provide additional perspective on the breadth of the opportunity for the NaviSci™ System, as well as updates to our patent portfolio and scientific and business advisory teams.

As always, thank you for your continued interest and support in Navigation Sciences.

Sincerely,
Alan.